Atlas Trials

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Clinical trial NCT06308575 · WITHDRAWN

Trial details

NCT number
NCT06308575
Sponsor
M.D. Anderson Cancer Center
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Olfactory NeuroblastomaRecurrent Olfactory Neuroblastoma
Start date
2024-11-01
Primary completion
2024-11-05
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.